Shane Moynihan
Question:727. Deputy Shane Moynihan asked the Minister for Health when a drug treatment for neurofibromatosis (details supplied) will be made available for patients by the HSE. [47109/26]
View answerTuesday, 23 June 2026
Questions (727)
Written answers
Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the HSE has been asked to provide an update in this matter.
The HSE has advised that Selumetinib (Koselugo®) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above is reimbursed via the High Tech Scheme since the 1st June 2026.